# Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens

> **NCT00591188** · PHASE2 · COMPLETED · sponsor: **Kidney Cancer Research Bureau** · enrollment: 49 (estimated)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** capecitabine, interferon-alpha

## Key facts

- **NCT ID:** NCT00591188
- **Lead sponsor:** Kidney Cancer Research Bureau
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-05
- **Final completion:** —
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2009-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00591188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00591188, "Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00591188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*